NLRP3 and endothelial dysfunction: The SGLT2 inhibitor drug class has been shown to exert anti-inflammatory actions by suppressing the activation of P3 receptor inflammasome activity (NLRP3), anti-fibrotic affects by stimulating M2 macrophages and inhibiting myofibroblast differentiation [19] and improves endothelial dysfunction [20].